A case of Streptococcus intermedius empyema

Annals of Pharmacotherapy

Volumn 40, Issue 6, 2006, Pages 1208-1210

  Wargo, Kurt A ^a,c   McConnell, Victoria J ^b,c   Higginbotham, Steven A ^a  

^a AUBURN UNIVERSITY   (United States)

^b and Clinical Center   (United States)

^c Huntsville Regional Medical Campus ^*  (United States)

Author keywords

Antimicrobial therapy; Community acquired pneumonia; Empyema; Streptococcus intermedius

Indexed keywords

CARVEDILOL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FUROSEMIDE; LEVOFLOXACIN; LEVOTHYROXINE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POTASSIUM CHLORIDE; PREDNISONE; TELITHROMYCIN;

AGED; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; BACTERIUM CULTURE; CASE REPORT; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DISEASE EXACERBATION; FEMALE; HEART FAILURE; HUMAN; HYPOTHYROIDISM; LUNG SURGERY; PHYSICAL EXAMINATION; PLEURA EMPYEMA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS INTERMEDIUS; STREPTOCOCCUS MILLERI; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 33745082802     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G704     Document Type: Article

References (15)

1. Han JK, Kerschner JE. Streptococcus milleri: an organism for head and neck infections and abscess. Arch Otolaryngol Head Neck Surg 2001;127:650-4.
2. Porta G, Rodriguez-Carballeira M, Gomez L, et al. Thoracic infection caused by Streptococcus milleri. Eur Respir J 1998;12:357-62.
3. Galea JL, De Souza A, Beggs D, Spyt T. The surgical management of empyema thoracis. J R Coll Surg Edinb 1997;42:15-8.
4. Jerng JS, Hsueh PR, Teng LJ, Lee LN, Yang PC, Luh KT. Empyema thoracis and lung abscess caused by viridans streptococci. Am J Respir Crit Care Med 1997;156:1508-14.
5. Shinzato T, Saito A. The Streptococcus milleri group as a cause of pulmonary infections. Clin Infect Dis 1995;21(suppl 3):S238-43.
6. Wong CA, Donald F, Macfarlane JT. Streptococcus milleri pulmonary disease: a review and clinical description of 25 patients. Thorax 1995;50:1093-6.
7. Roson B, Carratala J, Fernandez-Sabe N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004;164:502-8.
8. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405-33.
9. Marinella MA, Harrington GD, Standiford TJ. Empyema necessitans due to Streptococcus milleri. Clin Infect Dis 1996;23:203-4.
10. Tracy M, Wanahita A, Shuhatovich Y, Goldsmith EA, Clarridge JE 3rd, Musher DM. Antibiotic susceptibilities of genetically characterized Streptococcus milleri group strains. Antimicrob Agents Chemother 2001;45:1511-4.
11. Yamamoto N, Kubota T, Tohyama M, et al. Trends in antimicrobial susceptibility of the Streptococcus milleri group. J Infect Chemother 2002;8:134-7.
12. Limia A, Jimenez ML, Alarcon T, Lopez-Brea M. Five-year analysis of antimicrobial susceptibility of the Streptococcus milleri group. Eur J Clin Microbiol Infect Dis 1999;18:440-4.
13. Teixeira LR, Sasse SA, Villarino MA, Nguyen T, Mulligan ME, Light RW. Antibiotic levels in empyemic pleural fluid. Chest 2000;117:1734-9.
14. Strahilevitz J, Lev A, Levi I, Fridman E, Rubinstein E. Experimental pneumococcal pleural empyema model: the effect of moxifloxacin. J Antimicrob Chemother 2003;51:665-9.
15. Liapakis IE, Kottakis I, Tzatzarakis MN, et al. Penetration of newer quinolones in the empyema fluid. Eur Respir J 2004;24:466-70.